SEC Comment Letter 0000000000-23-009549 to RayzeBio, Inc. (CIK 0001825367)
RayzeBio, Inc. (CIK 0001825367)
Date: Aug. 29, 2023 · CIK: 0001825367 · Accession: 0000000000-23-009549
AI Filing Summary & Sentiment
File numbers found in text: 333-274193
Letter
United States securities and exchange commission logo August 29, 2023 Ken Song, M.D. President and Chief Executive Officer RayzeBio, Inc. 5505 Morehouse Drive, Suite 300 San Diego, CA 92121 Re:RayzeBio, Inc. Registration Statement on Form S-1 Filed August 24, 2023 File No. 333-274193 Dear Ken Song: We have reviewed your amended registration statement and have the following comments. In some of our comments, we may ask you to provide us with information so we may better understand your disclosure. Please respond to this letter by amending your registration statement and providing the requested information. If you do not believe our comments apply to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response. After reviewing any amendment to your registration statement and the information you provide in response to these comments, we may have additional comments. Unless we note otherwise, our references to prior comments are to comments in our August 18, 2023 letter. Registration Statement on Form S-1, filed August 24, 2023 General 1.Please revise your registration statement to disclose the identity of the selling stockholder and the number of shares that the selling stockholder will sell in the offering.
FirstName LastNameKen Song, M.D. Comapany NameRayzeBio, Inc. August 29, 2023 Page 2 FirstName LastName Ken Song, M.D. RayzeBio, Inc. August 29, 2023 Page 2 You may contact Gary Newberry at 202-551-3761 or Kevin Vaughn at 202-551-3494 if you have questions regarding comments on the financial statements and related matters. Please contact Joshua Gorsky at 202-551-7836 or Margaret Schwartz at 202-551-7153 with any other questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Terren J. O'Connor, Esq.
Show Raw Text
United States securities and exchange commission logo
August 29, 2023
Ken Song, M.D.
President and Chief Executive Officer
RayzeBio, Inc.
5505 Morehouse Drive, Suite 300
San Diego, CA 92121
Re:RayzeBio, Inc.
Registration Statement on Form S-1
Filed August 24, 2023
File No. 333-274193
Dear Ken Song:
We have reviewed your amended registration statement and have the following
comments. In some of our comments, we may ask you to provide us with information so we
may better understand your disclosure.
Please respond to this letter by amending your registration statement and providing the
requested information. If you do not believe our comments apply to your facts and
circumstances or do not believe an amendment is appropriate, please tell us why in your
response.
After reviewing any amendment to your registration statement and the information you
provide in response to these comments, we may have additional comments. Unless we note
otherwise, our references to prior comments are to comments in our August 18, 2023 letter.
Registration Statement on Form S-1, filed August 24, 2023
General
1.Please revise your registration statement to disclose the identity of the selling stockholder
and the number of shares that the selling stockholder will sell in the offering.
FirstName LastNameKen Song, M.D.
Comapany NameRayzeBio, Inc.
August 29, 2023 Page 2
FirstName LastName
Ken Song, M.D.
RayzeBio, Inc.
August 29, 2023
Page 2
You may contact Gary Newberry at 202-551-3761 or Kevin Vaughn at 202-551-3494 if
you have questions regarding comments on the financial statements and related matters. Please
contact Joshua Gorsky at 202-551-7836 or Margaret Schwartz at 202-551-7153 with any other
questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Terren J. O'Connor, Esq.